TrialBritish journal of haematology2021

Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.

Jorge J Castillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.